These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 20333709)

  • 1. Oral antiplatelet therapy in PCI patients.
    Sharma SK
    Catheter Cardiovasc Interv; 2010 Mar; 75 Suppl 1():S7-14. PubMed ID: 20333709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study.
    Savonitto S; Ambrosini V; Marzocchi A; Tolaro S; Petronio AS; Galassi AR; Bongo AS; Gaglione A; Bolognese L; ;
    Ital Heart J; 2005 Feb; 6(2):106-18. PubMed ID: 15819503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet activation and progression to complications.
    Kereiakes DJ; Michelson AD
    Rev Cardiovasc Med; 2006; 7(2):75-81. PubMed ID: 16915126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controversies surrounding platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention and acute coronary syndromes.
    Harrington RA
    Semin Thromb Hemost; 2004 Dec; 30(6):639-47. PubMed ID: 15630670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiplatelet intervention in acute coronary syndrome.
    Arora RR; Rai F
    Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiplatelet therapy in acute coronary syndromes.
    Aragam KG; Bhatt DL
    J Cardiovasc Pharmacol Ther; 2011 Mar; 16(1):24-42. PubMed ID: 20924098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use.
    Capodanno D; Milluzzo RP; Angiolillo DJ
    Ther Adv Cardiovasc Dis; 2019; 13():1753944719893274. PubMed ID: 31823688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycoprotein inhibitors in patients on chronic anticoagulation: safe enough or too much risk?
    Marín F; Bonacasa B; Valdés M
    Thromb Haemost; 2010 Jan; 103(1):11-2. PubMed ID: 20062940
    [No Abstract]   [Full Text] [Related]  

  • 9. [Blockers of platelet glycoprotein IIb/IIIa-receptors in the treatment of patients with acute coronary syndrome and during transcutaneous coronary interventions].
    Fettser DV; Preobrazhenskiĭ DV; Batyraliev TA; Sidorenko BA; Aĭtach V
    Ter Arkh; 2009; 81(1):84-7. PubMed ID: 19253720
    [No Abstract]   [Full Text] [Related]  

  • 10. Platelet function testing and implications for clinical practice.
    Collet JP; Montalescot G
    J Cardiovasc Pharmacol Ther; 2009 Sep; 14(3):157-69. PubMed ID: 19721130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiplatelet therapy in percutaneous coronary intervention: a critical review of the 2007 AHA/ACC/SCAI guidelines and beyond.
    Cohen M
    Catheter Cardiovasc Interv; 2009 Oct; 74(4):579-97. PubMed ID: 19472347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial.
    Yong G; Rankin J; Ferguson L; Thom J; French J; Brieger D; Chew DP; Dick R; Eccleston D; Hockings B; Walters D; Whelan A; Eikelboom JW
    Am Heart J; 2009 Jan; 157(1):60.e1-9. PubMed ID: 19081397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of upstream antiplatelet therapy use before primary percutaneous coronary intervention for acute ST-elevation myocardial infarction (from the CRUSADE National Quality Improvement Initiative).
    Alexander D; Mann N; Ou FS; Peterson ED; Ohman EM; Gibler WB; Roe MT
    Am J Cardiol; 2008 Nov; 102(10):1335-40. PubMed ID: 18993151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myocardial protection with a beta blocker and glycoprotein IIb/IIIa inhibitor during PCI: attractive concept, but limited evidence of benefit.
    Leesar MA
    Catheter Cardiovasc Interv; 2008 Oct; 72(4):498-9. PubMed ID: 18819148
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage.
    Kimmelstiel C; Badar J; Covic L; Waxman S; Weintraub A; Jacques S; Kuliopulos A
    Thromb Res; 2005; 116(1):55-66. PubMed ID: 15850609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
    O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
    J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients.
    Lee DS; Bhatt DL; Moliterno DJ; Peacock WF; Ellis SG; Topol EJ
    J Invasive Cardiol; 2004 Feb; 16(2):46-51. PubMed ID: 14760188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiplatelet therapy in patients with anticoagulants undergoing percutaneous coronary stenting (from STENTIng and oral antiCOagulants [STENTICO]).
    Gilard M; Blanchard D; Helft G; Carrier D; Eltchaninoff H; Belle L; Finet G; Le Breton H; Boschat J;
    Am J Cardiol; 2009 Aug; 104(3):338-42. PubMed ID: 19616664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary syndromes.
    Ivandic BT; Kurz K; Keck F; Staritz P; Lehrke S; Katus HA; Giannitsis E
    Thromb Haemost; 2008 Oct; 100(4):648-54. PubMed ID: 18841288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolving antithrombotic treatment strategies for acute ST-elevation myocardial infarction.
    Kandzari DE
    Rev Cardiovasc Med; 2006; 7 Suppl 4():S29-37. PubMed ID: 17224888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.